{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:24:05Z","timestamp":1791390245672,"version":"4.3.3"},"reference-count":82,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.neurol.2025.04.012","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T07:12:59Z","timestamp":1749453179000},"page":"597-607","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["French guidelines for the diagnosis and management of MOG antibody-associated disease"],"prefix":"10.1016","volume":"181","author":[{"given":"L.","family":"Giorgi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Marignier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Pique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Maurey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Papeix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Ciron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Collongues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Cheuret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Zephir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Vukusic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Doret-Dion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-T.","family":"Abi Warde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.-L.","family":"Poulat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Barreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Deschamps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Audoin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Mannes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Yver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Lattaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Maillart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Deiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9_Supplement_2","key":"10.1016\/j.neurol.2025.04.012_bib0415","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1212\/WNL.0000000000002820","article-title":"Pediatric transverse myelitis","volume":"87","author":"Absoud","year":"2016","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.neurol.2025.04.012_bib0420","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1007\/s00415-021-10914-x","article-title":"Relapse activity in the chronic phase of anti-myelin-oligodendrocyte glycoprotein antibody-associated disease","volume":"269","author":"Akaishi","year":"2022","journal-title":"J Neurol"},{"key":"10.1016\/j.neurol.2025.04.012_bib0425","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3389\/fneur.2020.00089","article-title":"Case series: myelin oligodendrocyte glycoprotein-immunoglobulin g-related disease spectrum","volume":"11","author":"Alshamrani","year":"2020","journal-title":"Front Neurol"},{"issue":"1","key":"10.1016\/j.neurol.2025.04.012_bib0430","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3390\/ijms22010100","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease: current insights into the disease pathophysiology, diagnosis and management","volume":"22","author":"Ambrosius","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.neurol.2025.04.012_bib0435","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1474-4422(19)30488-0","article-title":"Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study","volume":"19","author":"Armangue","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2025.04.012_bib0440","article-title":"Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS","author":"Banks","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"10.1016\/j.neurol.2025.04.012_bib0445","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1136\/jnnp-2014-308346","article-title":"Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein","volume":"86","author":"Baumann","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2025.04.012_bib0450","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejpn.2020.10.002","article-title":"E.U. paediatric MOG consortium consensus: part 2 - Neuroimaging features of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders","volume":"29","author":"Baumann","year":"2020","journal-title":"Eur J Paediatr Neurol"},{"issue":"4","key":"10.1016\/j.neurol.2025.04.012_bib0455","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s00415-018-8781-3","article-title":"MRI of the first event in pediatric acquired demyelinating syndromes with antibodies to myelin oligodendrocyte glycoprotein","volume":"265","author":"Baumann","year":"2018","journal-title":"J Neurol"},{"key":"10.1016\/j.neurol.2025.04.012_bib0460","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.msard.2019.05.006","article-title":"The clinical spectrum of anti-MOG associated acquired demyelinating disorders: three case-reports","volume":"33","author":"Bellinvia","year":"2019","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"10.1016\/j.neurol.2025.04.012_bib0465","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1111\/ene.13483","article-title":"CLIPPERS mimickers: relapsing brainstem encephalitis associated with anti-MOG antibodies","volume":"25","author":"Berzero","year":"2018","journal-title":"Eur J Neurol"},{"issue":"10","key":"10.1016\/j.neurol.2025.04.012_bib0470","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1007\/s00415-017-8615-8","article-title":"Optic neuritis in patients with anti-MOG antibodies spectrum disorder: MRI and clinical features from a large multicentric cohort in France","volume":"264","author":"Biotti","year":"2017","journal-title":"J Neurol"},{"issue":"12","key":"10.1016\/j.neurol.2025.04.012_bib0475","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1177\/1352458518765677","article-title":"Late-onset neutropenia and neurological relapse, during long-term rituximab therapy in myelin oligodendrocyte glycoprotein-antibody spectrum disorder","volume":"24","author":"Biotti","year":"2018","journal-title":"Mult Scler Houndmills Basingstoke Engl"},{"key":"10.1016\/j.neurol.2025.04.012_bib0480","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jns.2017.08.3254","article-title":"Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: clinical and paraclinical characteristics in Algerian patients","volume":"381","author":"Bouzar","year":"2017","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.neurol.2025.04.012_bib0485","doi-asserted-by":"crossref","first-page":"577078","DOI":"10.1016\/j.jneuroim.2019.577078","article-title":"The clinical presentation and treatment of MOG antibody disease at a single academic center: A case series","volume":"337","author":"Brayo","year":"2019","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.neurol.2025.04.012_bib0490","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejpn.2020.10.007","article-title":"E.U. paediatric MOG consortium consensus: Part 4 - Outcome of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders","volume":"29","author":"Bruijstens","year":"2020","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.neurol.2025.04.012_bib0495","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.ejpn.2020.10.006","article-title":"E.U. paediatric MOG consortium consensus: Part 1 - Classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders","volume":"29","author":"Bruijstens","year":"2020","journal-title":"Eur J Paediatr Neurol"},{"issue":"5","key":"10.1016\/j.neurol.2025.04.012_bib0500","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1111\/ene.14746","article-title":"The long-term outcome of MOGAD: An observational national cohort study of 61 patients","volume":"28","author":"Deschamps","year":"2021","journal-title":"Eur J Neurol"},{"issue":"3","key":"10.1016\/j.neurol.2025.04.012_bib0505","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1001\/jamaneurol.2018.4053","article-title":"Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody","volume":"76","author":"Dubey","year":"2019","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2025.04.012_bib0510","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ajo.2018.07.020","article-title":"Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: clinical characteristics, radiologic clues, and outcome","volume":"195","author":"Chen","year":"2018","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"10.1016\/j.neurol.2025.04.012_bib0515","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1177\/1352458519849511","article-title":"Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies: a retrospective multicentric study","volume":"26","author":"Ciron","year":"2020","journal-title":"Mult Scler Houndmills Basingstoke Engl"},{"issue":"1","key":"10.1016\/j.neurol.2025.04.012_bib0520","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/ana.25909","article-title":"Clinical features and risk of relapse in children and adults with myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"89","author":"Cobo-Calvo","year":"2021","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.neurol.2025.04.012_bib0525","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol"},{"issue":"6","key":"10.1016\/j.neurol.2025.04.012_bib0530","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1136\/bjophthalmol-2019-314845","article-title":"MOG-Ab prevalence in optic neuritis and clinical predictive factors for diagnosis","volume":"104","author":"Ducloyer","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.neurol.2025.04.012_bib0535","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.msard.2018.10.013","article-title":"Comparing myelin oligodendrocyte glycoprotein antibody (MOG-Ab) and non MOG-Ab associated optic neuritis: clinical course and treatment outcome","volume":"27","author":"Etemadifar","year":"2019","journal-title":"Mult Scler Relat Disord"},{"issue":"10","key":"10.1016\/j.neurol.2025.04.012_bib0540","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.jfo.2019.06.006","article-title":"Neuropathie optique dans le syndrome des anticorps anti MOG positif","volume":"42","author":"Merabtene","year":"2019","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.neurol.2025.04.012_bib0545","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ejpn.2020.04.002","article-title":"High association of MOG-IgG antibodies in children with bilateral optic neuritis","volume":"27","author":"Wendel","year":"2020","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.neurol.2025.04.012_bib0550","article-title":"Neuropathies optiques inflammatoires","author":"Toanen","year":"2016","journal-title":"PubMed [Internet]"},{"issue":"3","key":"10.1016\/j.neurol.2025.04.012_bib0555","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jpp.2021.02.004","article-title":"Prise en charge de la neuropathie optique inflammatoire de l\u2019enfant","volume":"34","author":"Cheuret","year":"2021","journal-title":"J P\u00e9diatrie Pu\u00e9riculture"},{"issue":"1","key":"10.1016\/j.neurol.2025.04.012_bib0560","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/WNO.0000000000000669","article-title":"Unfavorable structural and functional outcomes in myelin oligodendrocyte glycoprotein antibody-associated optic neuritis","volume":"39","author":"Jelcic","year":"2019","journal-title":"J Neuro-Ophthalmol"},{"key":"10.1016\/j.neurol.2025.04.012_bib0565","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jns.2019.03.014","article-title":"Clinical characteristics and outcomes of myelin oligodendrocyte glycoprotein antibody-seropositive optic neuritis in varying age groups: a cohort study in China","volume":"400","author":"Song","year":"2019","journal-title":"J Neurol Sci"},{"issue":"4","key":"10.1016\/j.neurol.2025.04.012_bib0570","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/1352458515593406","article-title":"Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis","volume":"22","author":"Ramanathan","year":"2016","journal-title":"Mult Scler Houndmills Basingstoke Engl"},{"issue":"2","key":"10.1016\/j.neurol.2025.04.012_bib0575","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/ene.14089","article-title":"Clinical, imaging and follow-up study of optic neuritis associated with myelin oligodendrocyte glycoprotein antibody: a multicentre study of 62 adult patients","volume":"27","author":"Shor","year":"2020","journal-title":"Eur J Neurol"},{"issue":"1\u20132","key":"10.1016\/j.neurol.2025.04.012_bib0580","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.neurol.2020.06.016","article-title":"MRI characteristics of MOG-Ab associated disease in adults: An update","volume":"177","author":"Shor","year":"2021","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.neurol.2025.04.012_bib0585","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.msard.2019.01.021","article-title":"Radiological characteristics of myelin oligodendrocyte glycoprotein antibody disease","volume":"29","author":"Salama","year":"2019","journal-title":"Mult Scler Relat Disord"},{"issue":"9","key":"10.1016\/j.neurol.2025.04.012_bib0590","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1007\/s00415-018-8956-y","article-title":"Myelin oligodendrocyte glycoprotein-positive optic neuritis masquerading as pseudotumor cerebri at presentation","volume":"265","author":"Lotan","year":"2018","journal-title":"J Neurol"},{"issue":"1","key":"10.1016\/j.neurol.2025.04.012_bib0595","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/01658107.2019.1607883","article-title":"Myelin oligodendrocyte glycoprotein antibody (MOG-IgG)-positive optic perineuritis","volume":"44","author":"Lopez-Chiriboga","year":"2020","journal-title":"Neuro-Ophthalmol Aeolus Press"},{"key":"10.1016\/j.neurol.2025.04.012_bib0600","series-title":"OCT en ophtalmologie: rapport 2019","author":"Korobelnik","year":"2019"},{"issue":"14","key":"10.1016\/j.neurol.2025.04.012_bib0605","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1177\/1352458518815596","article-title":"Spinal cord lesions and atrophy in NMOSD with AQP4-IgG and MOG-IgG associated autoimmunity","volume":"25","author":"Chien","year":"2019","journal-title":"Mult Scler Houndmills Basingstoke Engl"},{"issue":"4","key":"10.1016\/j.neurol.2025.04.012_bib0610","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1001\/jamaneurol.2017.4601","article-title":"Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"75","author":"Hacohen","year":"2018","journal-title":"JAMA Neurol"},{"issue":"6","key":"10.1016\/j.neurol.2025.04.012_bib0615","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1007\/s00415-020-09755-x","article-title":"MOG encephalomyelitis: distinct clinical, MRI and CSF features in patients with longitudinal extensive transverse myelitis as first clinical presentation","volume":"267","author":"Loos","year":"2020","journal-title":"J Neurol"},{"issue":"14","key":"10.1016\/j.neurol.2025.04.012_bib0620","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1212\/01.wnl.0000472753.44905.98","article-title":"Anti-MOG antibodies with longitudinally extensive transverse myelitis preceded by CLIPPERS","volume":"85","author":"Taieb","year":"2015","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.neurol.2025.04.012_bib0625","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1212\/WNL.59.4.499","article-title":"Proposed diagnostic criteria and nosology of acute transverse myelitis","volume":"59","year":"2002","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.neurol.2025.04.012_bib0630","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1007\/s00415-019-09440-8","article-title":"Unilateral cortical FLAIR-hyperintense Lesions in Anti-MOG-associated Encephalitis with Seizures (FLAMES): characterization of a distinct clinico-radiographic syndrome","volume":"266","author":"Budhram","year":"2019","journal-title":"J Neurol"},{"issue":"11","key":"10.1016\/j.neurol.2025.04.012_bib0635","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1080\/00207454.2020.1720676","article-title":"Unilateral cerebral cortical encephalitis with epilepsy: a possible special phenotype of MOG antibody-associated disorders","volume":"130","author":"Tao","year":"2020","journal-title":"Int J Neurosci"},{"issue":"2","key":"10.1016\/j.neurol.2025.04.012_bib0640","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1212\/NXI.0000000000000322","article-title":"MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy","volume":"4","author":"Ogawa","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"issue":"5","key":"10.1016\/j.neurol.2025.04.012_bib0645","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.1212\/NXI.0000000000000141","article-title":"NMDA receptor antibodies: a rare association in inflammatory demyelinating diseases","volume":"2","author":"Ramberger","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"issue":"1","key":"10.1016\/j.neurol.2025.04.012_bib0650","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/s12974-016-0719-z","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: brainstem involvement - frequency, presentation and outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J Neuroinflammation"},{"issue":"4","key":"10.1016\/j.neurol.2025.04.012_bib0655","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1055\/s-0041-1726289","article-title":"Progressive leukodystrophy-like demyelinating syndromes with MOG-antibodies in children: a rare under-recognized phenotype","volume":"52","author":"Yazbeck","year":"2021","journal-title":"Neuropediatrics"},{"issue":"4","key":"10.1016\/j.neurol.2025.04.012_bib0660","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/dmcn.13649","article-title":"\u2018Leukodystrophy-like\u2019 phenotype in children with myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"60","author":"Hacohen","year":"2018","journal-title":"Dev Med Child Neurol"},{"issue":"2","key":"10.1016\/j.neurol.2025.04.012_bib0665","doi-asserted-by":"crossref","first-page":"e543","DOI":"10.1212\/NXI.0000000000000543","article-title":"Cranial nerve involvement in patients with MOG antibody-associated disease","volume":"6","author":"Cobo-Calvo","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"issue":"5","key":"10.1016\/j.neurol.2025.04.012_bib0670","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s10072-018-3668-8","article-title":"Bilateral trigeminal root entry zone enhancement in MOG-IgG-associated brainstem encephalitis","volume":"40","author":"Shen","year":"2019","journal-title":"Neurol Sci"},{"key":"10.1016\/j.neurol.2025.04.012_bib0675","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejpn.2020.11.001","article-title":"E.U. paediatric MOG consortium. E.U. paediatric MOG consortium consensus: Part 3 - Biomarkers of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders","volume":"29","author":"Armangue","year":"2020","journal-title":"Eur J Paediatr Neurol"},{"issue":"2","key":"10.1016\/j.neurol.2025.04.012_bib0680","doi-asserted-by":"crossref","first-page":"e674","DOI":"10.1212\/NXI.0000000000000674","article-title":"International multicenter examination of MOG antibody assays","volume":"7","author":"Reindl","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"10.1016\/j.neurol.2025.04.012_bib0685","doi-asserted-by":"crossref","first-page":"116673","DOI":"10.1016\/j.jns.2020.116673","article-title":"Deciphering anti-MOG IgG antibodies: clinical and radiological spectrum, and comparison of antibody detection assays","volume":"410","author":"Tzartos","year":"2020","journal-title":"J Neurol Sci"},{"issue":"9","key":"10.1016\/j.neurol.2025.04.012_bib0690","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1136\/jnnp-2018-317969","article-title":"CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications","volume":"89","author":"Kaneko","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2025.04.012_bib0695","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneuroim.2015.10.002","article-title":"Increased interleukin-6 correlates with myelin oligodendrocyte glycoprotein antibodies in pediatric monophasic demyelinating diseases and multiple sclerosis","volume":"289","author":"Horellou","year":"2015","journal-title":"J Neuroimmunol"},{"issue":"2","key":"10.1016\/j.neurol.2025.04.012_bib0700","doi-asserted-by":"crossref","first-page":"e0149411","DOI":"10.1371\/journal.pone.0149411","article-title":"B Cell, Th17, and neutrophil related cerebrospinal fluid cytokine\/chemokines are elevated in MOG antibody associated demyelination","volume":"11","author":"Kothur","year":"2016","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.neurol.2025.04.012_bib0705","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s12974-020-01825-1","article-title":"Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 2: results from 108 lumbar punctures in 80 pediatric patients","volume":"17","author":"Jarius","year":"2020","journal-title":"J Neuroinflammation"},{"issue":"11","key":"10.1016\/j.neurol.2025.04.012_bib0710","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1001\/jamaneurol.2018.1814","article-title":"Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders","volume":"75","author":"L\u00f3pez-Chiriboga","year":"2018","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.neurol.2025.04.012_bib0715","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/jamaneurol.2019.2940","article-title":"Serial anti-myelin oligodendrocyte glycoprotein antibody analyses and outcomes in children with demyelinating syndromes","volume":"77","author":"Waters","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2025.04.012_bib0720","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejpn.2020.10.005","article-title":"E.U. paediatric MOG consortium consensus: part 5 - Treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders","volume":"29","author":"Bruijstens","year":"2020","journal-title":"Eur J Paediatr Neurol"},{"issue":"1","key":"10.1016\/j.neurol.2025.04.012_bib0725","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J Neuroinflammation"},{"issue":"1","key":"10.1016\/j.neurol.2025.04.012_bib0730","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12974-019-1525-1","article-title":"Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease","volume":"16","author":"Cobo-Calvo","year":"2019","journal-title":"J Neuroinflammation"},{"issue":"2","key":"10.1016\/j.neurol.2025.04.012_bib0735","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1212\/WNL.0000000000009758","article-title":"Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder","volume":"95","author":"Chen","year":"2020","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.neurol.2025.04.012_bib0740","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/jca.21705","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the writing committee of the american society for apheresis: the eighth special issue","volume":"34","author":"Padmanabhan","year":"2019","journal-title":"J Clin Apheresis"},{"issue":"3","key":"10.1016\/j.neurol.2025.04.012_bib0745","doi-asserted-by":"crossref","first-page":"e705","DOI":"10.1212\/NXI.0000000000000705","article-title":"Long-term efficacy of mycophenolate mofetil in myelin oligodendrocyte glycoprotein antibody-associated disorders: a prospective study","volume":"7","author":"Li","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"issue":"10","key":"10.1016\/j.neurol.2025.04.012_bib0750","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1177\/1352458516678474","article-title":"Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders","volume":"23","author":"Montcuquet","year":"2017","journal-title":"Mult Scler Houndmills Basingstoke Engl"},{"issue":"12","key":"10.1016\/j.neurol.2025.04.012_bib0755","doi-asserted-by":"crossref","first-page":"4537","DOI":"10.1007\/s00415-020-10236-4","article-title":"Efficacy and safety of long-term immunotherapy in adult patients with MOG antibody disease: a systematic analysis","volume":"268","author":"Lu","year":"2021","journal-title":"J Neurol"},{"issue":"2","key":"10.1016\/j.neurol.2025.04.012_bib0760","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","article-title":"Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination","volume":"89","author":"Ramanathan","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2025.04.012_bib0765","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.msard.2019.04.021","article-title":"Successful intravenous immunoglobulin treatment in relapsing MOG-antibody-associated disease","volume":"32","author":"Tsantes","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurol.2025.04.012_bib0770","doi-asserted-by":"crossref","first-page":"102251","DOI":"10.1016\/j.msard.2020.102251","article-title":"Treatment of MOG-IgG-associated disorder with rituximab: an international study of 121 patients","volume":"44","author":"Whittam","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"10.1016\/j.neurol.2025.04.012_bib0775","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/ana.25648","article-title":"Comparison of the response to rituximab between myelin oligodendrocyte glycoprotein and aquaporin-4 antibody diseases","volume":"87","author":"Durozard","year":"2020","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2025.04.012_bib0780","doi-asserted-by":"crossref","first-page":"101920","DOI":"10.1016\/j.msard.2019.101920","article-title":"Effectiveness of subcutaneous tocilizumab in neuromyelitis optica spectrum disorders","volume":"39","author":"Lotan","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurol.2025.04.012_bib0785","doi-asserted-by":"crossref","first-page":"102483","DOI":"10.1016\/j.msard.2020.102483","article-title":"Off-label use of tocilizumab in neuromyelitis optica spectrum disorders and MOG-antibody-associated diseases: a case-series","volume":"46","author":"Rigal","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurol.2025.04.012_bib0790","unstructured":"Clinical characteristics and outcomes of myelin oligodendrocyte glycoprotein antibody-seropositive optic neuritis in varying age groups: A cohort study in China. PubMed [Internet], 2019. doi: 10.1016\/j.jns.2019.03.014. [cit\u00e9 28 mars 2025] Disponible sur: https:\/\/pubmed.ncbi.nlm.nih.gov\/30904690\/."},{"issue":"9","key":"10.1016\/j.neurol.2025.04.012_bib0795","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1212\/WNL.0000000000004312","article-title":"Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome","volume":"89","author":"Hennes","year":"2017","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.neurol.2025.04.012_bib0800","doi-asserted-by":"crossref","first-page":"101235","DOI":"10.1016\/j.neurad.2024.101235","article-title":"MRI management of NMOSD and MOGAD: proposals from the French Expert Group NOMADMUS","volume":"52","author":"Durand-Dubief","year":"2025","journal-title":"J Neuroradiol J Neuroradiol"},{"issue":"7","key":"10.1016\/j.neurol.2025.04.012_bib0805","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/S1474-4422(17)30158-8","article-title":"International society for magnetic resonance in medicine. Gadolinium deposition in the brain: summary of evidence and recommendations","volume":"16","author":"Gulani","year":"2017","journal-title":"Lancet Neurol"},{"issue":"15","key":"10.1016\/j.neurol.2025.04.012_bib0810","doi-asserted-by":"crossref","first-page":"e2006-15","DOI":"10.1212\/WNL.0000000000011744","article-title":"Pregnancy in patients with AQP4-Ab, MOG-Ab, or double-negative neuromyelitis optica disorder","volume":"96","author":"Collongues","year":"2021","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.neurol.2025.04.012_bib0815","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1136\/jnnp-2020-323982","article-title":"Neuromyelitis optica spectrum disorder: pregnancy-related attack and predictive risk factors","volume":"92","author":"Wang","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2025.04.012_bib0820","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.msard.2018.02.006","article-title":"MOG-antibody demyelinating diseases: a case of post-partum severe rhombencephalitis and transverse myelitis","volume":"21","author":"Vecchio","year":"2018","journal-title":"Mult Scler Relat Disord"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378725005363?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378725005363?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T01:15:21Z","timestamp":1762218921000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378725005363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":82,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0035378725005363"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2025.04.012","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"French guidelines for the diagnosis and management of MOG antibody-associated disease","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2025.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}